



Curated by Peter Lansberg,
a Dutch lipidologist and educator, and
reviewed by prof. Philip Barter, Past President of the
International Atherosclerosis Society.

The IAS statin literature update will keep you up-to-date with all recent statin publications, using a curated approach to select relevant articles.

Statin publications September 2021

Add on treatments

1. Chiang CW. Meta-analysis Comparing the Effect of Combined Omega-3 + Statin Therapy Versus Statin Therapy Alone on Coronary Artery Plaques. *Am J Cardiol* 2021; 158:149-150. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34465459>
2. Schiele F, Pérez de Isla L, Arca M, Vlachopoulos C. Is it Time for Single-Pill Combinations in Dyslipidemia? *Am J Cardiovasc Drugs* 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34549371>
3. Bhagavathula AS, Vidyasaga K, Gebreyohannes EA, Tesfaye W. Risk of Gastrointestinal Bleeding on Treatment With Statin Alone or With Concomitant Administration of Warfarin: A Systematic Review and Meta-analysis of 5.3 Million Participants. *The Annals of pharmacotherapy* 2021:10600280211049727. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34595940>
4. Bouabdallaoui N, Tardif JC. Repurposing Colchicine for Heart Disease. *Annu Rev Pharmacol Toxicol* 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34587458>

5. Kwon M, Nam GH, Jung H *et al.* Statin in combination with cisplatin makes favorable tumor-immune microenvironment for immunotherapy of head and neck squamous cell carcinoma. Cancer letters 2021; 522:198-210.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34571082>
6. Blaum C, Brunner FJ, Goßling A *et al.* Target Populations and Treatment Cost for Bempedoic Acid and PCSK9 Inhibitors: A Simulation Study in a Contemporary CAD Cohort. Clinical therapeutics 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34462126>
7. Park MS, Youn JC, Kim EJ *et al.* Efficacy and Safety of Fenofibrate-Statin Combination Therapy in Patients With Inadequately Controlled Triglyceride Levels Despite Previous Statin Monotherapy: A Multicenter, Randomized, Double-blind, Phase IV Study. Clinical therapeutics 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34518033>
8. Shah T, McCarthy M, Nasir I *et al.* Design and rationale of the colchicine/statin for the prevention of COVID-19 complications (COLSTAT) trial. Contemporary clinical trials 2021;106547. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34461322>
9. Hernandez P, Passi N, Modarressi T *et al.* Clinical Management of Hypertriglyceridemia in the Prevention of Cardiovascular Disease and Pancreatitis. Curr Atheroscler Rep 2021; 23:72.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34515873>
10. Oyama K, Giugliano RP, Tang M *et al.* Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial. Eur Heart J 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34537830>
11. Sardari S, Fallahi F, Emadi F *et al.* Daily Consumption of Caper Fruit Along With Atorvastatin Has Synergistic Effects in Hyperlipidemic Patients: Randomized Clinical Trial. Galen Med J 2019; 8:e1345.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34466497>
12. Drobni ZD, Murphy SP, Alvi RM *et al.* Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors. Immunother Adv 2021; 1:ltab014. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34541581>
13. Verdickt S, Van der Schueren B, Vangoitsenhoven R *et al.* Belgian data of ODYSSEY APPRISE: stringent LDL-c targets are in reach when using all available tools. Int J Clin Pract 2021:e14916. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34551183>
14. Al Rijjal D, Liu Y, Lai M *et al.* Vascepa protects against high-fat diet-induced glucose intolerance, insulin resistance, and impaired β -cell function. iScience 2021; 24:102909. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34458694>
15. Sharma KK, Natani V, Gupta N *et al.* Statins in Patients with Uncomplicated Hypertension: A Prescription Audit. The Journal of the Association of Physicians of India 2021; 69:11-12. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34470187>

16. Collin BG, Raju D, Katsikas S. Statins, Enzyme CoQ(10) Supplement Use, and Cognitive Functioning. *J Geriatr Psychiatry Neurol* 2021;8919887211044747. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34493115>
17. Sun C, Zheng W, Liang L *et al.* Ezetimibe Improves Rosuvastatin Effects on Inflammation and Vascular Endothelial Function in Acute Coronary Syndrome Patients Undergoing PCI. *J Interv Cardiol* 2021; 2021:2995602. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34566523>
18. Gong Z, Zhan D, Nie M *et al.* Dexamethasone enhances the efficacy of atorvastatin in inhibiting excessively inflammation-induced abnormal angiogenesis by regulating macrophages. *Journal of neuroinflammation* 2021; 18:203. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34526068>
19. Liu CH, Lin YS, Sung PS *et al.* Colchicine Use and Risks of Stroke Recurrence in Acute Non-Cardiogenic Ischemic Stroke Patients: A Population-Based Cohort Study. *Journal of personalized medicine* 2021; 11. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34575712>
20. Joseph P, Roshandel G, Gao P *et al.* Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. *Lancet* 2021; 398:1133-1146. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34469765>
21. Zechner J, Britza SM, Farrington R *et al.* Flavonoid-statin interactions causing myopathy and the possible significance of OATP transport, CYP450 metabolism and mevalonate synthesis. *Life sciences* 2021:119975. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34560084>
22. Pinto LCS, Mello APQ, Izar MCO *et al.* Main differences between two highly effective lipid-lowering therapies in subclasses of lipoproteins in patients with acute myocardial infarction. *Lipids Health Dis* 2021; 20:124. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34587943>
23. Jamialahmadi T, Baratzadeh F, Reiner Ž *et al.* The Effects of Statin Dose, Lipophilicity, and Combination of Statins plus Ezetimibe on Circulating Oxidized Low-Density Lipoprotein Levels: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Mediators Inflamm* 2021; 2021:9661752. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34526854>
24. Cintra M, Pedraza Cezón LA, Martín Navarro JA *et al.* Acute renal failure due to rhabdomyolysis in relation to abiraterone and rosuvastatin. *Nefrologia (Engl Ed)* 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34503863>
25. Westergaard N, Tarnow L, Vermehren C. Comparison of Multidrug Use in the General Population and among Persons with Diabetes in Denmark for Drugs Having Pharmacogenomics (PGx) Based Dosing Guidelines. *Pharmaceuticals (Basel, Switzerland)* 2021; 14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34577599>

26. Niedzielski M, Broncel M, Gorzelak-Pabiś P, Woźniak E. A comparison of the effects of monotherapy with rosuvastatin, atorvastatin or ezetimibe versus combination treatment with rosuvastatin-ezetimibe and atorvastatin-ezetimibe on the integrity of vascular endothelial cells damaged by oxidized cholesterol. PLoS One 2021; 16:e0256996. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34492054>
27. Zhang X, Chen X, Liang Z *et al.* Pioglitazone combined with atorvastatin promotes plaque stabilization in a rabbit model. Vascular 2021:17085381211040992. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34470532>

Adherence

1. Rea F, Savaré L, Corrao G, Mancina G. Adherence to Lipid-Lowering Treatment by Single-Pill Combination of Statin and Ezetimibe. Adv Ther 2021; 38:5270-5285. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34480293>
2. Plutzky J, Benson MD, Chaney K *et al.* Population health management of low-density lipoprotein cholesterol via a remote, algorithmic, navigator-executed program. Am Heart J 2021; 243:15-27. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34481756>
3. Brown R, Lewsey J, Wild S *et al.* Associations of statin adherence and lipid targets with adverse outcomes in myocardial infarction survivors: a retrospective cohort study. BMJ Open 2021; 11:e054893. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34580105>
4. Tsioufis K, Castellano Vázquez JM, Sykara G *et al.* Real-world Evidence for Adherence and Persistence with Atorvastatin Therapy. Cardiology and therapy 2021; 10:445-464. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34586613>
5. Irawati S, Emmens JE, de Vos S *et al.* Association between adherence to statin therapy and low-density lipoprotein cholesterol (LDL-c) response in first-time users of standard-dose and low-dose statins: the PharmLines initiative. Current medical research and opinion 2021:1-6. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34555980>
6. Santoleri F, Romagnoli A, Costantini A. Adherence and persistence in the use of statins and ezetimibe over 8 years in a real-life study. Current medical research and opinion 2021:1-6. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34515600>
7. Campbell PJ, Axon DR, Taylor AM *et al.* Hypertension, cholesterol and diabetes medication adherence, health care utilization and expenditure in a Medicare Supplemental sample. Medicine (Baltimore) 2021; 100:e27143. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34477169>

8. Karvaly GB, Karádi I, Vincze I *et al.* A pharmacokinetics-based approach to the monitoring of patient adherence to atorvastatin therapy. Pharmacol Res Perspect 2021; 9:e00856. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34478238>

Atorvastatin/Rosuvastatin

1. Dey KK, Lodhi L, Ghosh M. Study of the Variation of the Electronic Distribution and Motional Dynamics of Two Independent Molecules of an Asymmetric Unit of Atorvastatin Calcium by Solid-State NMR Measurements. ACS omega 2021; 6:22752-22764. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34514246>
2. Emami S, Shayanfar A. Comments on "Dissolution Enhancement of Atorvastatin Calcium by Cocrystallization". Advanced pharmaceutical bulletin 2021; 11:578-579. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34513634>
3. Wu B, Wang Y, Li W *et al.* The effect of rosuvastatin on cardiogenic cerebral infarction. American journal of translational research 2021; 13:9444-9450. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34540064>
4. Jang YH, Choi KH, Song YB *et al.* Effects of Statin Intensity on Long-Term Outcomes after Coronary Artery Bypass Grafting. The Annals of thoracic surgery 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34555373>
5. Faraji E, Mohammadi M, Mahboobian MM. Development of the Binary and Ternary Atorvastatin Solid Dispersions: In Vitro and In Vivo Investigations. BioMed research international 2021; 2021:6644630. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34527740>
6. Kamuf J, Garcia Bardon A, Ziebart A *et al.* Influence of rosuvastatin treatment on cerebral inflammation and nitro-oxidative stress in experimental lung injury in pigs. BMC anesthesiology 2021; 21:224. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34517845>
7. Marti JLG, Beckwitt CH, Clark AM, Wells A. Atorvastatin facilitates chemotherapy effects in metastatic triple-negative breast cancer. Br J Cancer 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34462586>
8. Tsioufis K, Castellano Vázquez JM, Sykara G *et al.* Real-world Evidence for Adherence and Persistence with Atorvastatin Therapy. Cardiology and therapy 2021; 10:445-464. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34586613>
9. Chen J, Yan J, Li S *et al.* Atorvastatin inhibited TNF- α induced matrix degradation in rat nucleus pulposus cells by suppressing NLRP3 inflammasome activity and inducing autophagy through NF- κ B signaling. Cell Cycle 2021; 20:2160-2173. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34494933>
10. Anderson K, Nelson CH, Gong Q *et al.* Assessment of the Effect of Filgotinib on the Pharmacokinetics of Atorvastatin, Pravastatin, and Rosuvastatin in Healthy Adult

Participants. Clinical pharmacology in drug development 2021.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=34468080>

11. Le J, Liao Y, Li S *et al.* High-throughput LC-MS/MS Method for Simultaneous Determination of Pantoprazole and Atorvastatin in Rat Plasma: Application to a Pharmacokinetic Interaction Study. Current drug metabolism 2021; 22:481-490. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34455944>
12. Nastasi DR, Norman R, Moxon JV *et al.* The Potential Benefits and Costs of an Intensified Approach to Low Density Lipoprotein Cholesterol Lowering in People with Abdominal Aortic Aneurysm. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery 2021; 62:643-650. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34507892>
13. Gao Y, Li L, Yu J, Zhang Z. Rosuvastatin protects PC12 cells from hypoxia/reoxygenation-induced injury by inhibiting endoplasmic reticulum stress-induced apoptosis. Experimental and therapeutic medicine 2021; 22:1189. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34475979>
14. Zhang X, Wang D, Tian Y *et al.* Risk Factors for Atorvastatin as a Monotherapy for Chronic Subdural Hematoma: A Retrospective Multifactor Analysis. Frontiers in aging neuroscience 2021; 13:726592. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34539386>
15. Sardari S, Fallahi F, Emadi F *et al.* Daily Consumption of Caper Fruit Along With Atorvastatin Has Synergistic Effects in Hyperlipidemic Patients: Randomized Clinical Trial. Galen Med J 2019; 8:e1345. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34466497>
16. El-Say KM, Ahmed TA, Aljefri AH *et al.* Oleic acid-reinforced PEGylated polymethacrylate transdermal film with enhanced antidyslipidemic activity and bioavailability of atorvastatin: A mechanistic ex-vivo/in-vivo analysis. Int J Pharm 2021; 608:121057. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34461173>
17. Bai L, Scott MKD, Steinberg E *et al.* Computational drug repositioning of atorvastatin for ulcerative colitis. J Am Med Inform Assoc 2021; 28:2325-2335. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34529084>
18. Cai S, Gao Z. Atorvastatin inhibits proliferation and promotes apoptosis of colon cancer cells via COX-2/PGE2/ β -Catenin Pathway. J buon 2021; 26:1219-1225. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34564973>
19. Vijayakanthi N, Felner EI, Romero R, Daley TC. Rhabdomyolysis due to rosuvastatin in a patient with ROHHAD syndrome. J Clin Lipidol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34600840>
20. Moon IT, Kang SH, Lee W *et al.* Impact of statin intensity on adverse cardiac and cerebrovascular events in older adult patients with myocardial infarction. Journal of

- geriatric cardiology : JGC 2021; 18:609-622.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34527027>
21. Sun C, Zheng W, Liang L *et al.* Ezetimibe Improves Rosuvastatin Effects on Inflammation and Vascular Endothelial Function in Acute Coronary Syndrome Patients Undergoing PCI. J Interv Cardiol 2021; 2021:2995602.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34566523>
 22. Yang L, Li N, Yang L *et al.* Atorvastatin-Induced Absorption of Chronic Subdural Hematoma Is Partially Attributed to the Polarization of Macrophages. Journal of molecular neuroscience : MN 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34569007>
 23. Gong Z, Zhan D, Nie M *et al.* Dexamethasone enhances the efficacy of atorvastatin in inhibiting excessively inflammation-induced abnormal angiogenesis by regulating macrophages. Journal of neuroinflammation 2021; 18:203.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34526068>
 24. Delluc A, Ghanima W, Kovacs MJ *et al.* Statins for venous event reduction in patients with venous thromboembolism: A multicenter randomized controlled pilot trial assessing feasibility. Journal of thrombosis and haemostasis : JTH 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34564938>
 25. Pinto LCS, Mello APQ, Izar MCO *et al.* Main differences between two highly effective lipid-lowering therapies in subclasses of lipoproteins in patients with acute myocardial infarction. Lipids Health Dis 2021; 20:124.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34587943>
 26. Trias F, Pintó X, Corbella E *et al.* Differences in the diabetogenic effect of statins in patients with prediabetes. The PRELIPID study. Med Clin (Barc) 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34517987>
 27. Jamialahmadi T, Baratzadeh F, Reiner Ž *et al.* The Effects of Statin Dose, Lipophilicity, and Combination of Statins plus Ezetimibe on Circulating Oxidized Low-Density Lipoprotein Levels: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Mediators Inflamm 2021; 2021:9661752.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34526854>
 28. Duarte RRR, Copertino DC, Jr., Iñiguez LP *et al.* Identifying FDA-approved drugs with multimodal properties against COVID-19 using a data-driven approach and a lung organoid model of SARS-CoV-2 entry. Molecular medicine (Cambridge, Mass.) 2021; 27:105. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34503440>
 29. Cintra M, Pedraza Cezón LA, Martín Navarro JA *et al.* Acute renal failure due to rhabdomyolysis in relation to abiraterone and rosuvastatin. Nefrologia (Engl Ed) 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34503863>
 30. Li Z, Luo Y, Zhang J. Atorvastatin pretreatment alleviate the ischemic brain injury linked to peroxisome proliferator-activated receptor coactivator-1 α and angiogenic

- factors in diabetic mice. Neuro endocrinology letters 2021; 42:331-338.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34506097>
31. Wang QN, Bao XY, Zou ZX *et al.* The role of atorvastatin in collateral circulation formation induced by encephaloduroarteriosynangiosis: a prospective trial. Neurosurg Focus 2021; 51:E9. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34469867>
 32. Li R, Shi T, Xing E, Qu H. Atorvastatin calcium tablets on inflammatory factors, hemorheology and renal function damage indexes in patients with diabetic nephropathy. Pak J Med Sci 2021; 37:1392-1396.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34475918>
 33. Karvaly GB, Karádi I, Vincze I *et al.* A pharmacokinetics-based approach to the monitoring of patient adherence to atorvastatin therapy. Pharmacol Res Perspect 2021; 9:e00856. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34478238>
 34. Niedzielski M, Broncel M, Gorzelak-Pabiś P, Woźniak E. A comparison of the effects of monotherapy with rosuvastatin, atorvastatin or ezetimibe versus combination treatment with rosuvastatin-ezetimibe and atorvastatin-ezetimibe on the integrity of vascular endothelial cells damaged by oxidized cholesterol. PLoS One 2021; 16:e0256996. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34492054>
 35. McIver LA, Siddique MS. Atorvastatin. In: StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2021, StatPearls Publishing LLC.; 2021.
 36. Zhang X, Chen X, Liang Z *et al.* Pioglitazone combined with atorvastatin promotes plaque stabilization in a rabbit model. Vascular 2021:17085381211040992.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34470532>

Basic science

1. Dey KK, Lodhi L, Ghosh M. Study of the Variation of the Electronic Distribution and Motional Dynamics of Two Independent Molecules of an Asymmetric Unit of Atorvastatin Calcium by Solid-State NMR Measurements. ACS omega 2021; 6:22752-22764. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34514246>
2. Emami S, Shayanfar A. Comments on "Dissolution Enhancement of Atorvastatin Calcium by Cocrystallization". Advanced pharmaceutical bulletin 2021; 11:578-579.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34513634>
3. Wang C, Tang T, Wang Y *et al.* Simvastatin affects the PPAR α signaling pathway and causes oxidative stress and embryonic development interference in *Mugilogobius abei*. Aquatic toxicology (Amsterdam, Netherlands) 2021; 239:105951.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34467877>
4. Sanvee GM, Hitzfeld L, Bouitbir J, Krähenbühl S. mTORC2 is an important target for simvastatin-associated toxicity in C2C12 cells and mouse skeletal muscle - Roles of

- Rap1 geranylgeranylation and mitochondrial dysfunction. Biochem Pharmacol 2021; 192:114750. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34461118>
5. Faraji E, Mohammadi M, Mahboobian MM. Development of the Binary and Ternary Atorvastatin Solid Dispersions: In Vitro and In Vivo Investigations. BioMed research international 2021; 2021:6644630. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34527740>
 6. Kamuf J, Garcia Bardon A, Ziebart A *et al.* Influence of rosuvastatin treatment on cerebral inflammation and nitro-oxidative stress in experimental lung injury in pigs. BMC anesthesiology 2021; 21:224. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34517845>
 7. Kwon M, Nam GH, Jung H *et al.* Statin in combination with cisplatin makes favorable tumor-immune microenvironment for immunotherapy of head and neck squamous cell carcinoma. Cancer letters 2021; 522:198-210. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34571082>
 8. Chen J, Yan J, Li S *et al.* Atorvastatin inhibited TNF- α induced matrix degradation in rat nucleus pulposus cells by suppressing NLRP3 inflammasome activity and inducing autophagy through NF- κ B signaling. Cell Cycle 2021; 20:2160-2173. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34494933>
 9. Lim WJ, Lee M, Oh Y *et al.* Statins Decrease Programmed Death-Ligand 1 (PD-L1) by Inhibiting AKT and β -Catenin Signaling. Cells 2021; 10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34572136>
 10. Le J, Liao Y, Li S *et al.* High-throughput LC-MS/MS Method for Simultaneous Determination of Pantoprazole and Atorvastatin in Rat Plasma: Application to a Pharmacokinetic Interaction Study. Current drug metabolism 2021; 22:481-490. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34455944>
 11. Li G, Liu J. Analysis of Efficacy, Safety, and Prognostic Factors of mFOLFOX6 Regimen Combined with Cetuximab and Simvastatin in the Treatment of K-RAS Mutant Colorectal Cancer. Evidence-based complementary and alternative medicine : eCAM 2021; 2021:2280440. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34557254>
 12. Gao Y, Li L, Yu J, Zhang Z. Rosuvastatin protects PC12 cells from hypoxia/reoxygenation-induced injury by inhibiting endoplasmic reticulum stress-induced apoptosis. Experimental and therapeutic medicine 2021; 22:1189. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34475979>
 13. Li Q, Liu C, Deng L *et al.* Novel function of fluvastatin in attenuating oxidized low-density lipoprotein-induced endothelial cell ferroptosis in a glutathione peroxidase4- and cystine-glutamate antiporter-dependent manner. Experimental and therapeutic medicine 2021; 22:1275. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34594412>

14. Leal K, Saavedra K, Rebolledo C, Salazar LA. MicroRNAs hsa-miR-618 and hsa-miR-297 Might Modulate the Pleiotropic Effects Exerted by Statins in Endothelial Cells Through the Inhibition of ROCK2 Kinase: in-silico Approach. Frontiers in cardiovascular medicine 2021; 8:704175. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34485404>
15. Medwid S, Price HR, Taylor DP *et al.* Organic Anion Transporting Polypeptide 2B1 (OATP2B1) Genetic Variants: In Vitro Functional Characterization and Association With Circulating Concentrations of Endogenous Substrates. Frontiers in pharmacology 2021; 12:713567. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34594217>
16. Ren Y, Li L, Wang MM *et al.* Pravastatin attenuates sepsis-induced acute lung injury through decreasing pulmonary microvascular permeability via inhibition of Cav-1/eNOS pathway. Int Immunopharmacol 2021; 100:108077. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34464887>
17. El-Say KM, Ahmed TA, Aljefri AH *et al.* Oleic acid-reinforced PEGylated polymethacrylate transdermal film with enhanced antidyslipidemic activity and bioavailability of atorvastatin: A mechanistic ex-vivo/in-vivo analysis. Int J Pharm 2021; 608:121057. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34461173>
18. Al Rijjal D, Liu Y, Lai M *et al.* Vascepa protects against high-fat diet-induced glucose intolerance, insulin resistance, and impaired β -cell function. iScience 2021; 24:102909. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34458694>
19. Bai L, Scott MKD, Steinberg E *et al.* Computational drug repositioning of atorvastatin for ulcerative colitis. J Am Med Inform Assoc 2021; 28:2325-2335. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34529084>
20. Cai S, Gao Z. Atorvastatin inhibits proliferation and promotes apoptosis of colon cancer cells via COX-2/PGE2/ β -Catenin Pathway. J buon 2021; 26:1219-1225. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34564973>
21. Zhang X, Fan J, Chen C *et al.* Co-delivery of simvastatin and demineralized bone matrix hierarchically from nanosheet-based supramolecular hydrogels for osteogenesis. Journal of materials chemistry. B 2021; 9:7741-7750. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34586142>
22. Yang L, Li N, Yang L *et al.* Atorvastatin-Induced Absorption of Chronic Subdural Hematoma Is Partially Attributed to the Polarization of Macrophages. Journal of molecular neuroscience : MN 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34569007>
23. Aartsma-Rus A, Verhaart I, Wells D. Author's Response to: Rebuttal to: Simvastatin Treatment Does Not Ameliorate Muscle Pathophysiology in a Mouse Model for Duchenne Muscular Dystrophy, Verhaart et al. 2020. Journal of neuromuscular diseases 2021; 8:867-868. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34542081>

24. Whitehead NP, Kim MJ, Bible KL *et al.* Rebuttal to: Simvastatin Treatment Does Not Ameliorate Muscle Pathophysiology in a Mouse Model for Duchenne Muscular Dystrophy, Verhaart *et al.* 2020. Journal of neuromuscular diseases 2021; 8:865-866. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34542082>
25. Sanda K, Ayukawa Y, Yasunami N *et al.* Therapeutic effect of fluvastatin on medication-related osteonecrosis of the jaw. Journal of periodontology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34510440>
26. Fokina VM, Patrikeeva S, Wang XM *et al.* Role of Uptake Transporters OAT4, OATP2A1, and OATP1A2 in Human Placental Bio-disposition of Pravastatin. Journal of pharmaceutical sciences 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34597623>
27. Qian Y, Lei T, Patel PS *et al.* Direct Activation of Endothelial Cells by SARS-CoV-2 Nucleocapsid Protein Is Blocked by Simvastatin. J Virol 2021; 95:e0139621. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34549987>
28. Laskus-Zakrzewska A, Kazimierczak P, Kolmas J. Porous Composite Granules with Potential Function of Bone Substitute and Simvastatin Releasing System: A Preliminary Study. Materials (Basel, Switzerland) 2021; 14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34501158>
29. Sarsenbayeva A, Jui BN, Fanni G *et al.* Impaired HMG-CoA Reductase Activity Caused by Genetic Variants or Statin Exposure: Impact on Human Adipose Tissue, β -Cells and Metabolome. Metabolites 2021; 11. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34564389>
30. Zhao N, Yu M, Lan B *et al.* Simvastatin represses inflammation and cell apoptosis in copd rats via rho/rho kinase signaling pathway. Minerva Surg 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34523310>
31. Hasan H, Abd Rahim MH, Campbell L *et al.* Increasing Lovastatin Production by Re-routing the Precursors Flow of *Aspergillus terreus* via Metabolic Engineering. Molecular biotechnology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34546548>
32. Li Z, Luo Y, Zhang J. Atorvastatin pretreatment alleviate the ischemic brain injury linked to peroxisome proliferator-activated receptor coactivator-1 α and angiogenic factors in diabetic mice. Neuro endocrinology letters 2021; 42:331-338. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34506097>
33. Xu W, He Y, Zhang J *et al.* Simvastatin Blocks Reinstatement of Cocaine-induced Conditioned Place Preference in Male Mice with Brain Lipidome Remodeling. Neurosci Bull 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34491535>
34. Sri Iswari R, Dafip M, Purwantoyo E. Malondialdehyde (MDA) Production in Atherosclerosis Supplemented with Steamed Tomato. Pak J Biol Sci 2021; 24:319-325. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34486316>

35. Nandi U, Ajiboye AL, Patel P *et al.* Preparation of Solid Dispersions of Simvastatin and Soluplus Using a Single-Step Organic Solvent-Free Supercritical Fluid Process for the Drug Solubility and Dissolution Rate Enhancement. Pharmaceuticals (Basel, Switzerland) 2021; 14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34577546>
36. Afrin S, El Sabeh M, Islam MS *et al.* Simvastatin modulates estrogen signaling in uterine leiomyoma via regulating receptor palmitoylation, trafficking and degradation. Pharmacol Res 2021; 172:105856. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34461224>
37. Niedzielski M, Broncel M, Gorzelak-Pabiś P, Woźniak E. A comparison of the effects of monotherapy with rosuvastatin, atorvastatin or ezetimibe versus combination treatment with rosuvastatin-ezetimibe and atorvastatin-ezetimibe on the integrity of vascular endothelial cells damaged by oxidized cholesterol. PLoS One 2021; 16:e0256996. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34492054>
38. Mucha O, Podkalicka P, Kaziród K *et al.* Simvastatin does not alleviate muscle pathology in a mouse model of Duchenne muscular dystrophy. Skelet Muscle 2021; 11:21. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34479633>
39. Kale R, Shete P, Doifode D, Chitlange S. Analytical Method Development and Validation for Simultaneous Determination of Simvastatin and Mupirocin Using Reverse-Phase High-pressure Liquid Chromatographic Method. Turk J Pharm Sci 2021; 18:438-444. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34496550>

Cancer

1. Marti JLG, Beckwitt CH, Clark AM, Wells A. Atorvastatin facilitates chemotherapy effects in metastatic triple-negative breast cancer. Br J Cancer 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34462586>
2. Kwon M, Nam GH, Jung H *et al.* Statin in combination with cisplatin makes favorable tumor-immune microenvironment for immunotherapy of head and neck squamous cell carcinoma. Cancer letters 2021; 522:198-210. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34571082>
3. Pourlotfi A, Bass GA, Ahi Hulme R *et al.* Statin Use and Long-Term Mortality after Rectal Cancer Surgery. Cancers 2021; 13. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34503098>
4. Li G, Liu J. Analysis of Efficacy, Safety, and Prognostic Factors of mFOLFOX6 Regimen Combined with Cetuximab and Simvastatin in the Treatment of K-RAS Mutant Colorectal Cancer. Evidence-based complementary and alternative medicine : eCAM 2021; 2021:2280440. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34557254>
5. McKechnie T, Talwar G, Lee Y *et al.* Concurrent use of statins and neoadjuvant chemoradiotherapy for rectal cancer: a systematic review and meta-analysis.

International journal of colorectal disease 2021.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=34498133>

6. Karbasizade S, Ghorbani F, Ghasemi Darestani N *et al.* Comparison of therapeutic effects of statins and aloe vera mouthwash on chemotherapy induced oral mucositis. Int J Physiol Pathophysiol Pharmacol 2021; 13:110-116.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34540131>
7. Pourlotfi A, Ahl Hulme R, Forssten MP *et al.* Statin therapy and its association with long-term survival after colon cancer surgery. Surgery 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34507829>

Cost-effectiveness

1. Blaum C, Brunner FJ, Goßling A *et al.* Target Populations and Treatment Cost for Bempedoic Acid and PCSK9 Inhibitors: A Simulation Study in a Contemporary CAD Cohort. Clinical therapeutics 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34462126>
2. Nastasi DR, Norman R, Moxon JV *et al.* The Potential Benefits and Costs of an Intensified Approach to Low Density Lipoprotein Cholesterol Lowering in People with Abdominal Aortic Aneurysm. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery 2021; 62:643-650. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34507892>
3. Alghamdi A, Balkhi B, Altowajri A *et al.* Cost-Effectiveness Analysis of Evolocumab for the Treatment of Dyslipidemia in the Kingdom of Saudi Arabia. Pharmacoecon Open 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34582002>
4. Boettiger DC, Chattranukulchai P, Avihingsanon A *et al.* Atherosclerotic cardiovascular disease thresholds for statin initiation among people living with HIV in Thailand: A cost-effectiveness analysis. PLoS One 2021; 16:e0256926.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34499685>
5. Reinau D, Schur N, Twerenbold S *et al.* Utilisation patterns and costs of lipid-lowering drugs in Switzerland 2013-2019. Swiss Med Wkly 2021; 151:w30018.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34495601>

CVD

1. Wu B, Wang Y, Li W *et al.* The effect of rosuvastatin on cardiogenic cerebral infarction. American journal of translational research 2021; 13:9444-9450.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34540064>

2. Jang YH, Choi KH, Song YB *et al.* Effects of Statin Intensity on Long-Term Outcomes after Coronary Artery Bypass Grafting. The Annals of thoracic surgery 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34555373>
3. Brown R, Lewsey J, Wild S *et al.* Associations of statin adherence and lipid targets with adverse outcomes in myocardial infarction survivors: a retrospective cohort study. BMJ Open 2021; 11:e054893. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34580105>
4. Choi D, Chen Q, Goonewardena SN *et al.* Efficacy of Statin Therapy in Patients with Hospital Admission for COVID-19. Cardiovasc Drugs Ther 2021:1-9. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34524566>
5. Xenogiannis I, Zenati M, Bhatt DL *et al.* Saphenous Vein Graft Failure: From Pathophysiology to Prevention and Treatment Strategies. Circulation 2021; 144:728-745. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34460327>
6. Moledina SM, Shoaib A, Sun LY *et al.* Impact of the admitting ward on care quality and outcomes in non-ST-segment elevation myocardial infarction (NSTEMI): insights from a national registry. European heart journal. Quality of care & clinical outcomes 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34482404>
7. Hsu J, Iversen T, Price M *et al.* Myocardial Infarction Care Among The Elderly: Declining Treatment With Increasing Age In Two Countries. Health Aff (Millwood) 2021; 40:1483-1490. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34495733>
8. Asakura M, Hibi K, Shimizu W *et al.* Design and rationale of the EVOCATION trial: A prospective, randomized, exploratory study comparing the effect of evolocumab on coronary microvascular function after percutaneous coronary intervention in patients with stable coronary artery disease. J Cardiol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34518072>
9. Sun C, Zheng W, Liang L *et al.* Ezetimibe Improves Rosuvastatin Effects on Inflammation and Vascular Endothelial Function in Acute Coronary Syndrome Patients Undergoing PCI. J Interv Cardiol 2021; 2021:2995602. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34566523>
10. Yoon YH, Ahn JM, Kang DY *et al.* Association of Lipoprotein(a) With Recurrent Ischemic Events Following Percutaneous Coronary Intervention. JACC Cardiovasc Interv 2021; 14:2059-2068. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34556280>
11. Urbanowicz TK, Olasińska-Wiśniewska A, Michalak M *et al.* Cardioprotective Effect of Low Level of LDL Cholesterol on Perioperative Myocardial Injury in Off-Pump Coronary Artery Bypass Grafting. Medicina (Kaunas, Lithuania) 2021; 57. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34577798>
12. Cameron A, Cheng HK, Lee RP *et al.* Biomarkers for Atrial Fibrillation Detection After Stroke: Systematic Review and Meta-analysis. Neurology 2021; 97:e1775-e1789. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34504030>

13. Pracoń R, Demkow M, Anthopolos R *et al.* Optimal medical therapy in patients with stable coronary artery disease in Poland. The ISCHEMIA Trial experience. Pol Arch Intern Med 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34585554>

Endothelium/inflammation

1. Bouabdallaoui N, Tardif JC. Repurposing Colchicine for Heart Disease. Annu Rev Pharmacol Toxicol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34587458>
2. Shah T, McCarthy M, Nasir I *et al.* Design and rationale of the colchicine/statin for the prevention of COVID-19 complications (COLSTAT) trial. Contemporary clinical trials 2021:106547. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34461322>
3. Sun C, Zheng W, Liang L *et al.* Ezetimibe Improves Rosuvastatin Effects on Inflammation and Vascular Endothelial Function in Acute Coronary Syndrome Patients Undergoing PCI. J Interv Cardiol 2021; 2021:2995602. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34566523>
4. Gong Z, Zhan D, Nie M *et al.* Dexamethasone enhances the efficacy of atorvastatin in inhibiting excessively inflammation-induced abnormal angiogenesis by regulating macrophages. Journal of neuroinflammation 2021; 18:203. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34526068>
5. Alikiaii B, Heidari Z, Bagherniya M *et al.* The Effect of Statins on C-Reactive Protein in Stroke Patients: A Systematic Review of Clinical Trials. Mediators Inflamm 2021; 2021:7104934. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34489618>
6. Zhao N, Yu M, Lan B *et al.* Simvastatin represses inflammation and cell apoptosis in copd rats via rho/rho kinase signaling pathway. Minerva Surg 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34523310>
7. Li R, Shi T, Xing E, Qu H. Atorvastatin calcium tablets on inflammatory factors, hemorheology and renal function damage indexes in patients with diabetic nephropathy. Pak J Med Sci 2021; 37:1392-1396. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34475918>
8. Niedzielski M, Broncel M, Gorzelak-Pabiś P, Woźniak E. A comparison of the effects of monotherapy with rosuvastatin, atorvastatin or ezetimibe versus combination treatment with rosuvastatin-ezetimibe and atorvastatin-ezetimibe on the integrity of vascular endothelial cells damaged by oxidized cholesterol. PLoS One 2021; 16:e0256996. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34492054>

Ethnicity

1. Abbasloo S, Aghaei Meybodi HR, Fahimfar N *et al.* The associations of statin intake and the trabecular bone score and bone mineral density status in elderly Iranian

- individuals: a cross-sectional analysis of the Bushehr Elderly Health (BEH) program. Arch Osteoporos 2021; 16:144.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34570258>
2. Haque W, Grandhi GR, Kanaya AM *et al.* Implications of the 2019 American College of Cardiology/American Heart Association Primary Prevention Guidelines and potential value of the coronary artery calcium score among South Asians in the US: The Mediators of Atherosclerosis in South Asians Living in America (MASALA) study. Atherosclerosis 2021; 334:48-56.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34481175>
 3. Urina-Jassir M, Pacheco-Paez T, Paez-Canro C, Urina-Triana M. Statin associated adverse reactions in Latin America: a scoping review. BMJ Open 2021; 11:e050675.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34598987>
 4. Lin JL, Chen PS, Lin HW *et al.* Real-World Analyses of the Safety Outcome among a General Population Treated with Statins: An Asian Population-Based Study. J Atheroscler Thromb 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34497171>
 5. Lu Y, Zhang H, Lu J *et al.* Prevalence of Dyslipidemia and Availability of Lipid-Lowering Medications Among Primary Health Care Settings in China. JAMA network open 2021; 4:e2127573. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34586366>
 6. Wang T, Sun L, Xu L *et al.* Prevalence of dyslipidemia and gene polymorphisms of ABCB1 and SLCO1B1 in Han, Uygur, Kazak, Hui, Tatar, Kirgiz, and Sibe populations with coronary heart disease in Xinjiang, China. Lipids Health Dis 2021; 20:116.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34563206>
 7. Alghamdi A, Balkhi B, Altowajri A *et al.* Cost-Effectiveness Analysis of Evolocumab for the Treatment of Dyslipidemia in the Kingdom of Saudi Arabia. Pharmacoecon Open 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34582002>
 8. Boettiger DC, Chattranukulchai P, Avihingsanon A *et al.* Atherosclerotic cardiovascular disease thresholds for statin initiation among people living with HIV in Thailand: A cost-effectiveness analysis. PLoS One 2021; 16:e0256926.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34499685>

FH

1. Klevmoen M, Bogsrud MP, Retterstøl K *et al.* Loss of statin treatment years during pregnancy and breastfeeding periods in women with familial hypercholesterolemia. Atherosclerosis 2021; 335:8-15. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34520888>
2. Tokgozoglu L, Kayikcioglu M. Familial Hypercholesterolemia: Global Burden and Approaches. Current cardiology reports 2021; 23:151.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34480646>

3. Thompson GR. Use of apheresis in the age of new therapies for familial hypercholesterolaemia. Curr Opin Lipidol 2021; 32:363-369. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34561311>
4. Eid WE, Sapp EH, Flerlage E, Nolan JR. Lower-Intensity Statins Contributing to Gaps in Care for Patients With Primary Severe Hypercholesterolemia. J Am Heart Assoc 2021; 10:e020800. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34465130>

Genetics

1. Sarsenbayeva A, Jui BN, Fanni G *et al.* Impaired HMG-CoA Reductase Activity Caused by Genetic Variants or Statin Exposure: Impact on Human Adipose Tissue, β -Cells and Metabolome. Metabolites 2021; 11. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34564389>
2. Nusinovici S, Li H, Thakur S *et al.* High-Density Lipoprotein 3 Cholesterol and Primary Open-Angle Glaucoma: Metabolomics and Mendelian Randomization Analyses. Ophthalmology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34592243>

Guidelines

1. Vural Keskinler M, Bozkurt I, Telci Caklili O *et al.* COMPARISON OF REAL WORLD LIPID PROFILE OF PATIENTS WITH TYPE 2 DIABETES AND GUIDELINE RECOMMENDATIONS. Acta clinica Croatica 2021; 60:63-67. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34588723>
2. Plutzky J, Benson MD, Chaney K *et al.* Population health management of low-density lipoprotein cholesterol via a remote, algorithmic, navigator-executed program. Am Heart J 2021; 243:15-27. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34481756>
3. Haque W, Grandhi GR, Kanaya AM *et al.* Implications of the 2019 American College of Cardiology/American Heart Association Primary Prevention Guidelines and potential value of the coronary artery calcium score among South Asians in the US: The Mediators of Atherosclerosis in South Asians Living in America (MASALA) study. Atherosclerosis 2021; 334:48-56. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34481175>
4. Venkataraman P, Huynh Q, Nicholls SJ *et al.* Impact of a coronary artery calcium-guided statin treatment protocol on cardiovascular risk at 12 months: Results from a pragmatic, randomised controlled trial. Atherosclerosis 2021; 334:57-65. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34482089>
5. Brown R, Lewsey J, Wild S *et al.* Associations of statin adherence and lipid targets with adverse outcomes in myocardial infarction survivors: a retrospective cohort

- study. BMJ Open 2021; 11:e054893.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34580105>
6. Pavlović J, Greenland P, Franco OH *et al.* Recommendations and Associated Levels of Evidence for Statin Use in Primary Prevention of Cardiovascular Disease: A Comparison at Population Level of the American Heart Association/American College of Cardiology/Multisociety, US Preventive Services Task Force, Department of Veterans Affairs/Department of Defense, Canadian Cardiovascular Society, and European Society of Cardiology/European Atherosclerosis Society Clinical Practice Guidelines. Circ Cardiovasc Qual Outcomes 2021; 14:e007183.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34546786>
 7. Barrios V, Soronen J, Carter AM, Anastassopoulou A. Lipid management across Europe in the real-world setting: a rapid evidence review. Current medical research and opinion 2021:1-11. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34517739>
 8. Moledina SM, Shoaib A, Sun LY *et al.* Impact of the admitting ward on care quality and outcomes in non-ST-segment elevation myocardial infarction (NSTEMI): insights from a national registry. European heart journal. Quality of care & clinical outcomes 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34482404>
 9. Sharma KK, Natani V, Gupta N *et al.* Statins in Patients with Uncomplicated Hypertension: A Prescription Audit. The Journal of the Association of Physicians of India 2021; 69:11-12. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34470187>
 10. Rammos C, Steinmetz M, Lortz J *et al.* Peripheral artery disease in Germany (2009-2018): Prevalence, frequency of specialized ambulatory care and use of guideline-recommended therapy - A population-based study. Lancet Reg Health Eur 2021; 5:100113. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34557822>
 11. Grundy SM, Stone NJ, Blumenthal RS *et al.* High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better. Mayo Clinic proceedings 2021; 96:2660-2670.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34531060>
 12. Pracoń R, Demkow M, Anthopolos R *et al.* Optimal medical therapy in patients with stable coronary artery disease in Poland. The ISCHEMIA Trial experience. Pol Arch Intern Med 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34585554>

LDL- related parameters

1. Vural Keskinler M, Bozkurt I, Telci Caklili O *et al.* COMPARISON OF REAL WORLD LIPID PROFILE OF PATIENTS WITH TYPE 2 DIABETES AND GUIDELINE RECOMMENDATIONS. Acta clinica Croatica 2021; 60:63-67.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34588723>

2. Vrablik M, Seifert B, Parkhomenko A *et al.* Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study. *Atherosclerosis* 2021; 334:66-75. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34482090>
3. Brown R, Lewsey J, Wild S *et al.* Associations of statin adherence and lipid targets with adverse outcomes in myocardial infarction survivors: a retrospective cohort study. *BMJ Open* 2021; 11:e054893. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34580105>
4. Barrios V, Soronen J, Carter AM, Anastassopoulou A. Lipid management across Europe in the real-world setting: a rapid evidence review. *Current medical research and opinion* 2021;1-11. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34517739>
5. Eid WE, Sapp EH, Flerlage E, Nolan JR. Lower-Intensity Statins Contributing to Gaps in Care for Patients With Primary Severe Hypercholesterolemia. *J Am Heart Assoc* 2021; 10:e020800. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34465130>
6. Yoon YH, Ahn JM, Kang DY *et al.* Association of Lipoprotein(a) With Recurrent Ischemic Events Following Percutaneous Coronary Intervention. *JACC Cardiovasc Interv* 2021; 14:2059-2068. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34556280>
7. Wang T, Sun L, Xu L *et al.* Prevalence of dyslipidemia and gene polymorphisms of ABCB1 and SLCO1B1 in Han, Uygur, Kazak, Hui, Tatar, Kirgiz, and Sibe populations with coronary heart disease in Xinjiang, China. *Lipids Health Dis* 2021; 20:116. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34563206>
8. Grundy SM, Stone NJ, Blumenthal RS *et al.* High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better. *Mayo Clinic proceedings* 2021; 96:2660-2670. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34531060>
9. Urbanowicz TK, Olasińska-Wiśniewska A, Michalak M *et al.* Cardioprotective Effect of Low Level of LDL Cholesterol on Perioperative Myocardial Injury in Off-Pump Coronary Artery Bypass Grafting. *Medicina (Kaunas, Lithuania)* 2021; 57. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34577798>
10. Sahebkar A, Kiaie N, Gorabi AM *et al.* A comprehensive review on the lipid and pleiotropic effects of pitavastatin. *Progress in lipid research* 2021; 84:101127. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34509516>
11. Handhale A, Viljoen A, Wierzbicki AS. Elevated Lipoprotein(a): Background, Current Insights and Future Potential Therapies. *Vasc Health Risk Manag* 2021; 17:527-542. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34526771>

Lifestyle

1. Slade JM, Abela GS, Rozman M *et al.* The impact of statin therapy and aerobic exercise training on skeletal muscle and whole-body aerobic capacity. *Am Heart J Plus* 2021; 5. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34590057>

2. Kobayashi N, Shibata Y, Kurihara O *et al.* Impact of Low Body Mass Index on Features of Coronary Culprit Plaques and Outcomes in Patients With Acute Coronary Syndrome. Am J Cardiol 2021; 158:6-14.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34465460>
3. Costa RR, Vieira AF, Coconcelli L *et al.* Statin Use Improves Cardiometabolic Protection Promoted By Physical Training in an Aquatic Environment: A Randomized Clinical Trial. Arquivos brasileiros de cardiologia 2021; 117:270-278.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34495217>
4. Motta SBD, Toledes VC, Franzoni L. Statin Associated With Physical Training: A Perfect Combination. Arquivos brasileiros de cardiologia 2021; 117:279-280.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34495218>
5. Sardari S, Fallahi F, Emadi F *et al.* Daily Consumption of Caper Fruit Along With Atorvastatin Has Synergistic Effects in Hyperlipidemic Patients: Randomized Clinical Trial. Galen Med J 2019; 8:e1345.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34466497>
6. Protic O, Bonfigli AR, Antonicelli R. Nutraceutical Combinations in Hypercholesterolemia: Evidence from Randomized, Placebo-Controlled Clinical Trials. Nutrients 2021; 13. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34579005>

Meta-analyses

1. Chiang CW. Meta-analysis Comparing the Effect of Combined Omega-3 + Statin Therapy Versus Statin Therapy Alone on Coronary Artery Plaques. Am J Cardiol 2021; 158:149-150. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34465459>
2. Bhagavathula AS, Vidyasaga K, Gebreyohannes EA, Tesfaye W. Risk of Gastrointestinal Bleeding on Treatment With Statin Alone or With Concomitant Administration of Warfarin: A Systematic Review and Meta-analysis of 5.3 Million Participants. The Annals of pharmacotherapy 2021:10600280211049727.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34595940>
3. Vahedian-Azimi A, Bianconi V, Makvandi S *et al.* A systematic review and meta-analysis on the effects of statins on pregnancy outcomes. Atherosclerosis 2021; 336:1-11. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34601188>
4. Vahedian-Azimi A, Mohammadi SM, Banach M *et al.* Improved COVID-19 Outcomes following Statin Therapy: An Updated Systematic Review and Meta-analysis. BioMed research international 2021; 2021:1901772.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34568488>
5. Kessing LV. Incomplete systematic review and meta-analysis on statin use and depression risk - A commentary. Journal of affective disorders 2021; 295:215.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34481149>

6. Joseph P, Roshandel G, Gao P *et al.* Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet 2021; 398:1133-1146.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34469765>
7. Jamialahmadi T, Baratzadeh F, Reiner Ž *et al.* The Effects of Statin Dose, Lipophilicity, and Combination of Statins plus Ezetimibe on Circulating Oxidized Low-Density Lipoprotein Levels: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Mediators Inflamm 2021; 2021:9661752.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34526854>

Metabolic Syndrome - Diabetes

1. Vural Keskinler M, Bozkurt I, Telci Caklili O *et al.* COMPARISON OF REAL WORLD LIPID PROFILE OF PATIENTS WITH TYPE 2 DIABETES AND GUIDELINE RECOMMENDATIONS. Acta clinica Croatica 2021; 60:63-67.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34588723>
2. Vergès B, Hassid J, Rouland A *et al.* Liraglutide reduces plasma PCSK9 in patients with type 2 diabetes not treated with statins. Diabetes Metab 2021:101284.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34551355>
3. Jun JE, Jeong IK, Ahn KJ *et al.* Statin use for primary prevention in patients with type 2 diabetes: Can it benefit all ages? - A nationwide propensity-matched cohort study. Diabetes Res Clin Pract 2021; 180:109044.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34508736>
4. Shinohara K, Ikeda S, Enzan N *et al.* Efficacy of intensive lipid-lowering therapy with statins stratified by blood pressure levels in patients with type 2 diabetes mellitus and retinopathy: Insight from the EMPATHY study. Hypertension research : official journal of the Japanese Society of Hypertension 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34526672>
5. Al Rijjal D, Liu Y, Lai M *et al.* Vascepa protects against high-fat diet-induced glucose intolerance, insulin resistance, and impaired β -cell function. iScience 2021; 24:102909. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34458694>
6. Basu S, Flood D, Geldsetzer P *et al.* Estimated effect of increased diagnosis, treatment, and control of diabetes and its associated cardiovascular risk factors among low-income and middle-income countries: a microsimulation model. The Lancet. Global health 2021; 9:e1539-e1552.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34562369>
7. Campbell PJ, Axon DR, Taylor AM *et al.* Hypertension, cholesterol and diabetes medication adherence, health care utilization and expenditure in a Medicare

Supplemental sample. Medicine (Baltimore) 2021; 100:e27143.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=34477169>

8. Sarsenbayeva A, Jui BN, Fanni G *et al.* Impaired HMG-CoA Reductase Activity Caused by Genetic Variants or Statin Exposure: Impact on Human Adipose Tissue, β -Cells and Metabolome. Metabolites 2021; 11.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34564389>
9. Li Z, Luo Y, Zhang J. Atorvastatin pretreatment alleviate the ischemic brain injury linked to peroxisome proliferator-activated receptor coactivator-1 α and angiogenic factors in diabetic mice. Neuro endocrinology letters 2021; 42:331-338.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34506097>
10. Westergaard N, Tarnow L, Vermehren C. Comparison of Multidrug Use in the General Population and among Persons with Diabetes in Denmark for Drugs Having Pharmacogenomics (PGx) Based Dosing Guidelines. Pharmaceuticals (Basel, Switzerland) 2021; 14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34577599>

New Treatments

1. Volis I, Hislop E, Saliba W, Zafrir B. A safety and clinical efficacy analysis of PCSK9 monoclonal antibodies in patients with markedly elevated creatine phosphokinase levels. Am J Blood Res 2021; 11:399-404.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34540348>
2. Hardy J, Niman S, Goldfaden RF *et al.* A Review of the Clinical Pharmacology of Pelacarsen: A Lipoprotein(a)-Lowering Agent. Am J Cardiovasc Drugs 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34490591>
3. Oyama K, Giugliano RP, Tang M *et al.* Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial. Eur Heart J 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34537830>
4. Verdickt S, Van der Schueren B, Vangoitsenhoven R *et al.* Belgian data of ODYSSEY APPRISE: stringent LDL-c targets are in reach when using all available tools. Int J Clin Pract 2021:e14916. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34551183>
5. Tomoi Y, Soga Y, Imada K *et al.* Use of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor to Treat Cholesterol Crystal Embolisms after Catheterization: A Report of Three Cases. Intern Med 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34471031>
6. Asakura M, Hibi K, Shimizu W *et al.* Design and rationale of the EVOCATION trial: A prospective, randomized, exploratory study comparing the effect of evolocumab on coronary microvascular function after percutaneous coronary intervention in patients with stable coronary artery disease. J Cardiol 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34518072>

7. Gao F, Wang ZJ, Ma XT *et al.* Effect of alirocumab on coronary plaque in patients with coronary artery disease assessed by optical coherence tomography. Lipids Health Dis 2021; 20:106. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34511134>
8. Alghamdi A, Balkhi B, Altowaijri A *et al.* Cost-Effectiveness Analysis of Evolocumab for the Treatment of Dyslipidemia in the Kingdom of Saudi Arabia. Pharmacoecoon Open 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34582002>

Other

1. Pezel T, Paim LR, Coelho-Filho OR. For which HIV Patients Aspirin and Statins are Good? Arquivos brasileiros de cardiologia 2021; 117:376-377. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34495235>
2. Vahedian-Azimi A, Mohammadi SM, Banach M *et al.* Improved COVID-19 Outcomes following Statin Therapy: An Updated Systematic Review and Meta-analysis. BioMed research international 2021; 2021:1901772. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34568488>
3. Choi D, Chen Q, Goonewardena SN *et al.* Efficacy of Statin Therapy in Patients with Hospital Admission for COVID-19. Cardiovasc Drugs Ther 2021:1-9. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34524566>
4. Sahashi Y, Sahashi M, Hikasa Y. Effect of Pravastatin as an Adjunctive Therapeutic for Mitral Insufficiency with Hyperlipidemia in a Dog. Case Rep Vet Med 2021; 2021:6054125. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34532150>
5. Mizuno A, Patel MS, Park SH *et al.* Statin Prescribing Patterns During In-Person and Telemedicine Visits Before and During the COVID-19 Pandemic. Circ Cardiovasc Qual Outcomes 2021; 14:e008266. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34551588>
6. Brunet L, Mallon P, Fusco JS *et al.* Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living with HIV: Lipid Changes and Statin Underutilization. Clinical drug investigation 2021; 41:955-965. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34546533>
7. Mathur S, Janaudis-Ferreira T, Hemphill J *et al.* User-centered design features for digital health applications to support physical activity behaviors in solid organ transplant recipients: A qualitative study. Clinical transplantation 2021:e14472. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34510558>
8. Vergès B, Hassid J, Rouland A *et al.* Liraglutide reduces plasma PCSK9 in patients with type 2 diabetes not treated with statins. Diabetes Metab 2021:101284. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34551355>

9. Rimmer RA, Mace JC, Gill A *et al.* Association of statins with quality of life and olfaction in patients with chronic rhinosinusitis. International forum of allergy & rhinology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34510817>
10. Davoodi L, Jafarpour H, Oladi Z *et al.* Atorvastatin therapy in COVID-19 adult inpatients: A double-blind, randomized controlled trial. International journal of cardiology. Heart & vasculature 2021; 36:100875. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34541293>
11. Cilla A, López-García G, Collado-Díaz V *et al.* Hypercholesterolemic patients have higher eryptosis and erythrocyte adhesion to human endothelium independently of statin therapy. Int J Clin Pract 2021:e14771. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34473881>
12. Schembri Higgans J, Bowman S, Abela JE. COVID-19 associated pancreatitis: A mini case-series. Int J Surg Case Rep 2021; 87:106429. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34567954>
13. Tomoi Y, Soga Y, Imada K *et al.* Use of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor to Treat Cholesterol Crystal Embolisms after Catheterization: A Report of Three Cases. Intern Med 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34471031>
14. Meintrup D, Borgmann S, Seidl K *et al.* Specific Risk Factors for Fatal Outcome in Critically Ill COVID-19 Patients: Results from a European Multicenter Study. Journal of clinical medicine 2021; 10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34501301>
15. Zhang X, Chen Y, Tong N *et al.* Maternally inherited diabetes and deafness coexists with lipoprotein lipase gene mutation-associated severe hyperlipidemia that was resistant to fenofibrate and atorvastatin, but sensitive to bezafibrate: A case report. Journal of diabetes investigation 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34460997>
16. Rey JR, Merino Llorens JL, Iniesta Manjavacas Á M *et al.* Influence of statin treatment in a cohort of patients admitted for COVID-19. Med Clin (Barc) 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34511251>
17. Duarte RRR, Copertino DC, Jr., Iñiguez LP *et al.* Identifying FDA-approved drugs with multimodal properties against COVID-19 using a data-driven approach and a lung organoid model of SARS-CoV-2 entry. Molecular medicine (Cambridge, Mass.) 2021; 27:105. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34503440>
18. Wang QN, Bao XY, Zou ZX *et al.* The role of atorvastatin in collateral circulation formation induced by encephaloduroarteriosynangiosis: a prospective trial. Neurosurg Focus 2021; 51:E9. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34469867>
19. Nusinovici S, Li H, Thakur S *et al.* High-Density Lipoprotein 3 Cholesterol and Primary Open-Angle Glaucoma: Metabolomics and Mendelian Randomization Analyses. Ophthalmology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34592243>

20. Ayeh SK, Abbey EJ, Khalifa BAA *et al.* Statins use and COVID-19 outcomes in hospitalized patients. PLoS One 2021; 16:e0256899.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34506533>
21. Boettiger DC, Chattranukulchai P, Avihingsanon A *et al.* Atherosclerotic cardiovascular disease thresholds for statin initiation among people living with HIV in Thailand: A cost-effectiveness analysis. PLoS One 2021; 16:e0256926.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34499685>
22. Rossi C, Berta P, Curello S *et al.* The impact of COVID-19 pandemic on AMI and stroke mortality in Lombardy: Evidence from the epicenter of the pandemic. PLoS One 2021; 16:e0257910. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34597292>
23. Mucha O, Podkalicka P, Kaziród K *et al.* Simvastatin does not alleviate muscle pathology in a mouse model of Duchenne muscular dystrophy. Skelet Muscle 2021; 11:21. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34479633>

PAD and statins

1. Nastasi DR, Norman R, Moxon JV *et al.* The Potential Benefits and Costs of an Intensified Approach to Low Density Lipoprotein Cholesterol Lowering in People with Abdominal Aortic Aneurysm. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery 2021; 62:643-650. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34507892>
2. Rammos C, Steinmetz M, Lortz J *et al.* Peripheral artery disease in Germany (2009-2018): Prevalence, frequency of specialized ambulatory care and use of guideline-recommended therapy - A population-based study. Lancet Reg Health Eur 2021; 5:100113. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34557822>

Pleiotropic effects of statins

1. Sohrevardi SM, Nasab FS, Mirjalili MR *et al.* Effect of atorvastatin on delirium status of patients in the intensive care unit: a randomized controlled trial. Archives of medical science : AMS 2021; 17:1423-1428.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34522273>
2. Abbasloo S, Aghaei Meybodi HR, Fahimfar N *et al.* The associations of statin intake and the trabecular bone score and bone mineral density status in elderly Iranian individuals: a cross-sectional analysis of the Bushehr Elderly Health (BEH) program. Arch Osteoporos 2021; 16:144.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34570258>

3. Kamuf J, Garcia Bardon A, Ziebart A *et al.* Influence of rosuvastatin treatment on cerebral inflammation and nitro-oxidative stress in experimental lung injury in pigs. BMC anesthesiology 2021; 21:224.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34517845>
4. Marti JLG, Beckwitt CH, Clark AM, Wells A. Atorvastatin facilitates chemotherapy effects in metastatic triple-negative breast cancer. Br J Cancer 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34462586>
5. Kwon M, Nam GH, Jung H *et al.* Statin in combination with cisplatin makes favorable tumor-immune microenvironment for immunotherapy of head and neck squamous cell carcinoma. Cancer letters 2021; 522:198-210.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34571082>
6. Pourlofti A, Bass GA, Ahl Hulme R *et al.* Statin Use and Long-Term Mortality after Rectal Cancer Surgery. Cancers 2021; 13.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34503098>
7. Chen J, Yan J, Li S *et al.* Atorvastatin inhibited TNF- α induced matrix degradation in rat nucleus pulposus cells by suppressing NLRP3 inflammasome activity and inducing autophagy through NF- κ B signaling. Cell Cycle 2021; 20:2160-2173.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34494933>
8. Wei J, Liao JK, Bairey Merz CN. Challenging Statin Pleiotropy: Preeclampsia. Circulation 2021; 144:680-683. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34460319>
9. Kadoglou NPE, Velidakis N, Khattab E *et al.* The interplay between statins and adipokines. Is this another explanation of statins' 'pleiotropic' effects? Cytokine 2021; 148:155698. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34537488>
10. Di Spirito F, Schiavo L, Piloni V *et al.* Periodontal and Peri-Implant Diseases and Systemically Administered Statins: A Systematic Review. Dent J (Basel) 2021; 9.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34562974>
11. Chiu WC, Shan JC, Yang YH *et al.* Statins and the risks of decompensated liver cirrhosis and hepatocellular carcinoma determined in patients with alcohol use disorder. Drug Alcohol Depend 2021; 228:109096.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34600254>
12. Li G, Liu J. Analysis of Efficacy, Safety, and Prognostic Factors of mFOLFOX6 Regimen Combined with Cetuximab and Simvastatin in the Treatment of K-RAS Mutant Colorectal Cancer. Evidence-based complementary and alternative medicine : eCAM 2021; 2021:2280440. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34557254>
13. Gao Y, Li L, Yu J, Zhang Z. Rosuvastatin protects PC12 cells from hypoxia/reoxygenation-induced injury by inhibiting endoplasmic reticulum stress-induced apoptosis. Experimental and therapeutic medicine 2021; 22:1189.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34475979>

14. Li Q, Liu C, Deng L *et al.* Novel function of fluvastatin in attenuating oxidized low-density lipoprotein-induced endothelial cell ferroptosis in a glutathione peroxidase4- and cystine-glutamate antiporter-dependent manner. Experimental and therapeutic medicine 2021; 22:1275.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34594412>
15. Leal K, Saavedra K, Rebolledo C, Salazar LA. MicroRNAs hsa-miR-618 and hsa-miR-297 Might Modulate the Pleiotropic Effects Exerted by Statins in Endothelial Cells Through the Inhibition of ROCK2 Kinase: in-silico Approach. Frontiers in cardiovascular medicine 2021; 8:704175.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34485404>
16. Li C, Ma M, Dong S *et al.* Statin Treatment in the Acute Phase and the Risk of Post-stroke Pneumonia: A Retrospective Cohort Study. Frontiers in neurology 2021; 12:635079. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34552547>
17. Horn CL, Morales AL, Savard C *et al.* Role of Cholesterol-Associated Steatohepatitis in the Development of NASH. HepatoL Commun 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34558856>
18. Merkel M, Schneider C, Greinert R *et al.* Protective Effects of Statin Therapy in Cirrhosis Are Limited by a Common SLCO1B1 Transporter Variant. HepatoL Commun 2021; 5:1755-1766. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34558822>
19. Ren Y, Li L, Wang MM *et al.* Pravastatin attenuates sepsis-induced acute lung injury through decreasing pulmonary microvascular permeability via inhibition of Cav-1/eNOS pathway. Int Immunopharmacol 2021; 100:108077.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34464887>
20. McKechnie T, Talwar G, Lee Y *et al.* Concurrent use of statins and neoadjuvant chemoradiotherapy for rectal cancer: a systematic review and meta-analysis. International journal of colorectal disease 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34498133>
21. Chien CC, Chen PH, Chung CH *et al.* Association between Statins and Retinal Vascular Occlusion: A Population-Based Cohort Study. International journal of environmental research and public health 2021; 18.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34574786>
22. Karbasizade S, Ghorbani F, Ghasemi Darestani N *et al.* Comparison of therapeutic effects of statins and aloe vera mouthwash on chemotherapy induced oral mucositis. Int J Physiol Pathophysiol Pharmacol 2021; 13:110-116.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34540131>
23. Kessing LV. Incomplete systematic review and meta-analysis on statin use and depression risk - A commentary. Journal of affective disorders 2021; 295:215.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34481149>

24. Lu G, Li Z. Statin Therapy on Cognitive Decline and Incident Dementia. J Am Coll Cardiol 2021; 78:e101. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34593131>
25. Zhou Z, Ryan J, Ernst ME *et al.* Reply: Statin Therapy on Cognitive Decline and Incident Dementia. J Am Coll Cardiol 2021; 78:e103. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34593132>
26. Bai L, Scott MKD, Steinberg E *et al.* Computational drug repositioning of atorvastatin for ulcerative colitis. J Am Med Inform Assoc 2021; 28:2325-2335. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34529084>
27. Cai S, Gao Z. Atorvastatin inhibits proliferation and promotes apoptosis of colon cancer cells via COX-2/PGE2/ β -Catenin Pathway. J buon 2021; 26:1219-1225. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34564973>
28. Zhang X, Fan J, Chen C *et al.* Co-delivery of simvastatin and demineralized bone matrix hierarchically from nanosheet-based supramolecular hydrogels for osteogenesis. Journal of materials chemistry. B 2021; 9:7741-7750. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34586142>
29. Gong Z, Zhan D, Nie M *et al.* Dexamethasone enhances the efficacy of atorvastatin in inhibiting excessively inflammation-induced abnormal angiogenesis by regulating macrophages. Journal of neuroinflammation 2021; 18:203. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34526068>
30. Aartsma-Rus A, Verhaart I, Wells D. Author's Response to: Rebuttal to: Simvastatin Treatment Does Not Ameliorate Muscle Pathophysiology in a Mouse Model for Duchenne Muscular Dystrophy, Verhaart *et al.* 2020. Journal of neuromuscular diseases 2021; 8:867-868. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34542081>
31. Whitehead NP, Kim MJ, Bible KL *et al.* Rebuttal to: Simvastatin Treatment Does Not Ameliorate Muscle Pathophysiology in a Mouse Model for Duchenne Muscular Dystrophy, Verhaart *et al.* 2020. Journal of neuromuscular diseases 2021; 8:865-866. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34542082>
32. Sanda K, Ayukawa Y, Yasunami N *et al.* Therapeutic effect of fluvastatin on medication-related osteonecrosis of the jaw. Journal of periodontology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34510440>
33. Delluc A, Ghanima W, Kovacs MJ *et al.* Statins for venous event reduction in patients with venous thromboembolism: A multicenter randomized controlled pilot trial assessing feasibility. Journal of thrombosis and haemostasis : JTH 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34564938>
34. Kramer JJ, Gu L, Moreira D *et al.* Statin Use and Lower Urinary Tract Symptoms Incidence and Progression in Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial. The Journal of urology 2021:101097ju0000000000002199. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34544265>

35. Qian Y, Lei T, Patel PS *et al.* Direct Activation of Endothelial Cells by SARS-CoV-2 Nucleocapsid Protein Is Blocked by Simvastatin. J Virol 2021; 95:e0139621. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34549987>
36. Bartalena L, Piantanida E, Tanda ML. Statins for Graves' orbitopathy: a new tool for prevention and treatment? The lancet. Diabetes & endocrinology 2021; 9:726-727. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34592165>
37. Lanzolla G, Sabini E, Leo M *et al.* Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial. The lancet. Diabetes & endocrinology 2021; 9:733-742. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34592164>
38. Laskus-Zakrzewska A, Kazimierczak P, Kolmas J. Porous Composite Granules with Potential Function of Bone Substitute and Simvastatin Releasing System: A Preliminary Study. Materials (Basel, Switzerland) 2021; 14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34501158>
39. Zhao N, Yu M, Lan B *et al.* Simvastatin represses inflammation and cell apoptosis in copd rats via rho/rho kinase signaling pathway. Minerva Surg 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34523310>
40. Xu W, He Y, Zhang J *et al.* Simvastatin Blocks Reinstatement of Cocaine-induced Conditioned Place Preference in Male Mice with Brain Lipidome Remodeling. Neurosci Bull 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34491535>
41. Yun SJ, Byun SJ, Kim HJ *et al.* Statin use and pneumonia risk in Parkinson's disease. Parkinsonism & related disorders 2021; 91:124-127. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34601341>
42. Afrin S, El Sabeh M, Islam MS *et al.* Simvastatin modulates estrogen signaling in uterine leiomyoma via regulating receptor palmitoylation, trafficking and degradation. Pharmacol Res 2021; 172:105856. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34461224>
43. Sahebkar A, Kiaie N, Gorabi AM *et al.* A comprehensive review on the lipid and pleiotropic effects of pitavastatin. Progress in lipid research 2021; 84:101127. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34509516>
44. Pourlotfi A, Ahl Hulme R, Forssten MP *et al.* Statin therapy and its association with long-term survival after colon cancer surgery. Surgery 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34507829>

Primary Prevention

1. Vrablik M, Seifert B, Parkhomenko A *et al.* Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study. Atherosclerosis 2021; 334:66-75. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34482090>

2. Pavlović J, Greenland P, Franco OH *et al.* Recommendations and Associated Levels of Evidence for Statin Use in Primary Prevention of Cardiovascular Disease: A Comparison at Population Level of the American Heart Association/American College of Cardiology/Multisociety, US Preventive Services Task Force, Department of Veterans Affairs/Department of Defense, Canadian Cardiovascular Society, and European Society of Cardiology/European Atherosclerosis Society Clinical Practice Guidelines. Circ Cardiovasc Qual Outcomes 2021; 14:e007183.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34546786>
3. Saeed A, Zhu J, Thoma F *et al.* Cardiovascular Disease Risk-Based Statin Utilization and Associated Outcomes in a Primary Prevention Cohort: Insights From a Large Health Care Network. Circ Cardiovasc Qual Outcomes 2021; 14:e007485.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34455825>
4. Jun JE, Jeong IK, Ahn KJ *et al.* Statin use for primary prevention in patients with type 2 diabetes: Can it benefit all ages? - A nationwide propensity-matched cohort study. Diabetes Res Clin Pract 2021; 180:109044.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34508736>
5. Grigorian-Shamagian L, Edel K, Esteve-Pastor MA *et al.* Practical Decision Algorithms for the Use of the Cardiovascular Polypill in Secondary Prevention in Europe. Frontiers in cardiovascular medicine 2021; 8:663361.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34504874>
6. Nissen SE, Hutchinson HG, Wang TY *et al.* Technology-Assisted Self-Selection of Candidates for Nonprescription Statin Therapy. J Am Coll Cardiol 2021; 78:1114-1123. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34503680>
7. Sarraju A, Spencer-Bonilla G, Chung S *et al.* Statin Use in Older Adults for Primary Cardiovascular Disease Prevention Across a Spectrum of Cardiovascular Risk. Journal of general internal medicine 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34505981>
8. Lu Y, Zhang H, Lu J *et al.* Prevalence of Dyslipidemia and Availability of Lipid-Lowering Medications Among Primary Health Care Settings in China. JAMA network open 2021; 4:e2127573. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34586366>

Registry data

1. Bhagavathula AS, Vidyasaga K, Gebreyohannes EA, Tesfaye W. Risk of Gastrointestinal Bleeding on Treatment With Statin Alone or With Concomitant Administration of Warfarin: A Systematic Review and Meta-analysis of 5.3 Million Participants. The Annals of pharmacotherapy 2021:10600280211049727.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34595940>

2. Abbasloo S, Aghaei Meybodi HR, Fahimfar N *et al.* The associations of statin intake and the trabecular bone score and bone mineral density status in elderly Iranian individuals: a cross-sectional analysis of the Bushehr Elderly Health (BEH) program. Arch Osteoporos 2021; 16:144.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34570258>
3. Vrablik M, Seifert B, Parkhomenko A *et al.* Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study. Atherosclerosis 2021; 334:66-75. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34482090>
4. Pourlotfi A, Bass GA, Ahl Hulme R *et al.* Statin Use and Long-Term Mortality after Rectal Cancer Surgery. Cancers 2021; 13.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34503098>
5. Santoleri F, Romagnoli A, Costantini A. Adherence and persistence in the use of statins and ezetimibe over 8 years in a real-life study. Current medical research and opinion 2021:1-6. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34515600>
6. Chiu WC, Shan JC, Yang YH *et al.* Statins and the risks of decompensated liver cirrhosis and hepatocellular carcinoma determined in patients with alcohol use disorder. Drug Alcohol Depend 2021; 228:109096.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34600254>
7. Moledina SM, Shoaib A, Sun LY *et al.* Impact of the admitting ward on care quality and outcomes in non-ST-segment elevation myocardial infarction (NSTEMI): insights from a national registry. European heart journal. Quality of care & clinical outcomes 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34482404>
8. Li C, Ma M, Dong S *et al.* Statin Treatment in the Acute Phase and the Risk of Post-stroke Pneumonia: A Retrospective Cohort Study. Frontiers in neurology 2021; 12:635079. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34552547>
9. Chien CC, Chen PH, Chung CH *et al.* Association between Statins and Retinal Vascular Occlusion: A Population-Based Cohort Study. International journal of environmental research and public health 2021; 18.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34574786>
10. Sharma KK, Natani V, Gupta N *et al.* Statins in Patients with Uncomplicated Hypertension: A Prescription Audit. The Journal of the Association of Physicians of India 2021; 69:11-12. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34470187>
11. Lin JL, Chen PS, Lin HW *et al.* Real-World Analyses of the Safety Outcome among a General Population Treated with Statins: An Asian Population-Based Study. J Atheroscler Thromb 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34497171>
12. Sarraju A, Spencer-Bonilla G, Chung S *et al.* Statin Use in Older Adults for Primary Cardiovascular Disease Prevention Across a Spectrum of Cardiovascular Risk. Journal of general internal medicine 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34505981>

13. Moon IT, Kang SH, Lee W *et al.* Impact of statin intensity on adverse cardiac and cerebrovascular events in older adult patients with myocardial infarction. Journal of geriatric cardiology : JGC 2021; 18:609-622.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34527027>
14. Liu CH, Lin YS, Sung PS *et al.* Colchicine Use and Risks of Stroke Recurrence in Acute Non-Cardiogenic Ischemic Stroke Patients: A Population-Based Cohort Study. Journal of personalized medicine 2021; 11.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34575712>
15. Lu Y, Zhang H, Lu J *et al.* Prevalence of Dyslipidemia and Availability of Lipid-Lowering Medications Among Primary Health Care Settings in China. JAMA network open 2021; 4:e2127573. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34586366>
16. Joseph P, Roshandel G, Gao P *et al.* Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet 2021; 398:1133-1146.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34469765>
17. Urbanowicz TK, Olasińska-Wiśniewska A, Michalak M *et al.* Cardioprotective Effect of Low Level of LDL Cholesterol on Perioperative Myocardial Injury in Off-Pump Coronary Artery Bypass Grafting. Medicina (Kaunas, Lithuania) 2021; 57.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34577798>
18. Ayeh SK, Abbey EJ, Khalifa BAA *et al.* Statins use and COVID-19 outcomes in hospitalized patients. PLoS One 2021; 16:e0256899.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34506533>
19. Pourlotfi A, Ahl Hulme R, Forssten MP *et al.* Statin therapy and its association with long-term survival after colon cancer surgery. Surgery 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34507829>

Renal Disease

1. Chu CD, Powe NR, McCulloch CE *et al.* Trends in Chronic Kidney Disease Care in the US by Race and Ethnicity, 2012-2019. JAMA network open 2021; 4:e2127014.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34570204>
2. Li R, Shi T, Xing E, Qu H. Atorvastatin calcium tablets on inflammatory factors, hemorheology and renal function damage indexes in patients with diabetic nephropathy. Pak J Med Sci 2021; 37:1392-1396.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34475918>

Reviews

1. Hardy J, Niman S, Goldfaden RF *et al.* A Review of the Clinical Pharmacology of Pelacarsen: A Lipoprotein(a)-Lowering Agent. Am J Cardiovasc Drugs 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34490591>
2. Schiele F, Pérez de Isla L, Arca M, Vlachopoulos C. Is it Time for Single-Pill Combinations in Dyslipidemia? Am J Cardiovasc Drugs 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34549371>
3. Bouabdallaoui N, Tardif JC. Repurposing Colchicine for Heart Disease. Annu Rev Pharmacol Toxicol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34587458>
4. Urina-Jassir M, Pacheco-Paez T, Paez-Canro C, Urina-Triana M. Statin associated adverse reactions in Latin America: a scoping review. BMJ Open 2021; 11:e050675. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34598987>
5. Pavlović J, Greenland P, Franco OH *et al.* Recommendations and Associated Levels of Evidence for Statin Use in Primary Prevention of Cardiovascular Disease: A Comparison at Population Level of the American Heart Association/American College of Cardiology/Multisociety, US Preventive Services Task Force, Department of Veterans Affairs/Department of Defense, Canadian Cardiovascular Society, and European Society of Cardiology/European Atherosclerosis Society Clinical Practice Guidelines. Circ Cardiovasc Qual Outcomes 2021; 14:e007183. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34546786>
6. Hernandez P, Passi N, Modarressi T *et al.* Clinical Management of Hypertriglyceridemia in the Prevention of Cardiovascular Disease and Pancreatitis. Curr Atheroscler Rep 2021; 23:72. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34515873>
7. Kadoglou NPE, Velidakis N, Khatrab E *et al.* The interplay between statins and adipokines. Is this another explanation of statins' 'pleiotropic' effects? Cytokine 2021; 148:155698. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34537488>
8. Di Spirito F, Schiavo L, Pilone V *et al.* Periodontal and Peri-Implant Diseases and Systemically Administered Statins: A Systematic Review. Dent J (Basel) 2021; 9. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34562974>
9. Barre DE, Mizier-Barre KA. Selected 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors. A look into their use and potential in pre-diabetes and type 2 diabetes. Endocr Regul 2021; 55:182-192. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34523296>
10. Bulwa ZB, Mendelson SJ, Brorson JR. Acute Secondary Prevention of Ischemic Stroke: Overlooked No Longer. Frontiers in neurology 2021; 12:701168. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34566845>

11. Horn CL, Morales AL, Savard C *et al.* Role of Cholesterol-Associated Steatohepatitis in the Development of NASH. Hepatol Commun 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34558856>
12. Bhattarai AK, Acharya A, Karki PK. Use of Statins as Lipid Lowering Agent in Hypercholesterolemia in a Tertiary Care Hospital: A Descriptive Cross-sectional Study. JNMA J Nepal Med Assoc 2020; 58:1031-1035. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34506382>
13. Bartalena L, Piantanida E, Tanda ML. Statins for Graves' orbitopathy: a new tool for prevention and treatment? The lancet. Diabetes & endocrinology 2021; 9:726-727. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34592165>
14. Basu S, Flood D, Geldsetzer P *et al.* Estimated effect of increased diagnosis, treatment, and control of diabetes and its associated cardiovascular risk factors among low-income and middle-income countries: a microsimulation model. The Lancet. Global health 2021; 9:e1539-e1552. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34562369>
15. Alikiaii B, Heidari Z, Bagherniya M *et al.* The Effect of Statins on C-Reactive Protein in Stroke Patients: A Systematic Review of Clinical Trials. Mediators Inflamm 2021; 2021:7104934. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34489618>
16. Cintra M, Pedraza Cezón LA, Martín Navarro JA *et al.* Acute renal failure due to rhabdomyolysis in relation to abiraterone and rosuvastatin. Nefrologia (Engl Ed) 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34503863>
17. Sahebkar A, Kiaie N, Gorabi AM *et al.* A comprehensive review on the lipid and pleiotropic effects of pitavastatin. Progress in lipid research 2021; 84:101127. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34509516>
18. Mclver LA, Siddique MS. Atorvastatin. In: StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2021, StatPearls Publishing LLC.; 2021.
19. Handhle A, Viljoen A, Wierzbicki AS. Elevated Lipoprotein(a): Background, Current Insights and Future Potential Therapies. Vasc Health Risk Manag 2021; 17:527-542. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34526771>

Safety and side effects

1. Fidalgo C, Mendes A, Cunha R, Rodrigues F. Diagnosis of Statin-Induced Necrotizing Myopathy: Contribution of Anti-HMGCR Antibodies. Acta medica portuguesa 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34592132>
2. Slade JM, Abela GS, Rozman M *et al.* The impact of statin therapy and aerobic exercise training on skeletal muscle and whole-body aerobic capacity. Am Heart J Plus 2021; 5. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34590057>

3. Volis I, Hislop E, Saliba W, Zafrir B. A safety and clinical efficacy analysis of PCSK9 monoclonal antibodies in patients with markedly elevated creatine phosphokinase levels. Am J Blood Res 2021; 11:399-404.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34540348>
4. Bhagavathula AS, Vidyasaga K, Gebreyohannes EA, Tesfaye W. Risk of Gastrointestinal Bleeding on Treatment With Statin Alone or With Concomitant Administration of Warfarin: A Systematic Review and Meta-analysis of 5.3 Million Participants. The Annals of pharmacotherapy 2021:10600280211049727.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34595940>
5. Peterson MN, Dykhoff HJ, Crowson CS *et al.* Risk of rheumatoid arthritis diagnosis in statin users in a large nationwide US study. Arthritis Res Ther 2021; 23:244.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34537063>
6. Vahedian-Azimi A, Bianconi V, Makvandi S *et al.* A systematic review and meta-analysis on the effects of statins on pregnancy outcomes. Atherosclerosis 2021; 336:1-11. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34601188>
7. Sanvee GM, Hitzfeld L, Bouitbir J, Krähenbühl S. mTORC2 is an important target for simvastatin-associated toxicity in C2C12 cells and mouse skeletal muscle - Roles of Rap1 geranylgeranylation and mitochondrial dysfunction. Biochem Pharmacol 2021; 192:114750. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34461118>
8. Urina-Jassir M, Pacheco-Paez T, Paez-Canro C, Urina-Triana M. Statin associated adverse reactions in Latin America: a scoping review. BMJ Open 2021; 11:e050675.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34598987>
9. Anderson K, Nelson CH, Gong Q *et al.* Assessment of the Effect of Filgotinib on the Pharmacokinetics of Atorvastatin, Pravastatin, and Rosuvastatin in Healthy Adult Participants. Clinical pharmacology in drug development 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34468080>
10. Zhu Y, Chiang CW, Wang L *et al.* A multistate transition model for statin-induced myopathy and statin discontinuation. CPT Pharmacometrics Syst Pharmacol 2021; 10:1236-1244. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34562311>
11. Le J, Liao Y, Li S *et al.* High-throughput LC-MS/MS Method for Simultaneous Determination of Pantoprazole and Atorvastatin in Rat Plasma: Application to a Pharmacokinetic Interaction Study. Current drug metabolism 2021; 22:481-490.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34455944>
12. Barre DE, Mizier-Barre KA. Selected 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors. A look into their use and potential in pre-diabetes and type 2 diabetes. Endocr Regul 2021; 55:182-192.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34523296>
13. Medwid S, Price HR, Taylor DP *et al.* Organic Anion Transporting Polypeptide 2B1 (OATP2B1) Genetic Variants: In Vitro Functional Characterization and Association

- With Circulating Concentrations of Endogenous Substrates. Frontiers in pharmacology 2021; 12:713567. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34594217>
14. Merkel M, Schneider C, Greinert R *et al.* Protective Effects of Statin Therapy in Cirrhosis Are Limited by a Common SLCO1B1 Transporter Variant. HepatoI Commun 2021; 5:1755-1766. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34558822>
 15. Drobni ZD, Murphy SP, Alvi RM *et al.* Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors. Immunother Adv 2021; 1:ltab014. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34541581>
 16. Howard JP, Wood FA, Finegold JA *et al.* Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment. J Am Coll Cardiol 2021; 78:1210-1222. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34531021>
 17. Toth PP. That Myalgia of Yours Is Not From Statin Intolerance. J Am Coll Cardiol 2021; 78:1223-1226. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34531022>
 18. Lin JL, Chen PS, Lin HW *et al.* Real-World Analyses of the Safety Outcome among a General Population Treated with Statins: An Asian Population-Based Study. J Atheroscler Thromb 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34497171>
 19. Vijayakanthi N, Felner EI, Romero R, Daley TC. Rhabdomyolysis due to rosuvastatin in a patient with ROHHAD syndrome. J Clin Lipidol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34600840>
 20. Fokina VM, Patrikeeva S, Wang XM *et al.* Role of Uptake Transporters OAT4, OATP2A1, and OATP1A2 in Human Placental Bio-disposition of Pravastatin. Journal of pharmaceutical sciences 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34597623>
 21. Zechner J, Britza SM, Farrington R *et al.* Flavonoid-statin interactions causing myopathy and the possible significance of OATP transport, CYP450 metabolism and mevalonate synthesis. Life sciences 2021:119975. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34560084>
 22. Trias F, Pintó X, Corbella E *et al.* Differences in the diabetogenic effect of statins in patients with prediabetes. The PRELIPID study. Med Clin (Barc) 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34517987>
 23. Cameron A, Cheng HK, Lee RP *et al.* Biomarkers for Atrial Fibrillation Detection After Stroke: Systematic Review and Meta-analysis. Neurology 2021; 97:e1775-e1789. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34504030>
 24. Parikh P, Onuorah N, Vashisht P. A rare overlap of statin-induced anti-3-hydroxy-3-methyl-glutaryl-coenzyme A necrotizing autoimmune myositis and dermatomyositis. Rheumatol Adv Pract 2021; 5:rkab064. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34527856>

1. Wu B, Wang Y, Li W *et al.* The effect of rosuvastatin on cardiogenic cerebral infarction. American journal of translational research 2021; 13:9444-9450. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34540064>
2. Sohrevardi SM, Nasab FS, Mirjalili MR *et al.* Effect of atorvastatin on delirium status of patients in the intensive care unit: a randomized controlled trial. Archives of medical science : AMS 2021; 17:1423-1428. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34522273>
3. Ali L, Safan A, Kamran S *et al.* Acute Thromboembolic Ischemic Stroke From Complex Aortic Arch Plaque. Cureus 2021; 13:e16977. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34540387>
4. Baang HY, Sheth KN. Stroke Prevention After Intracerebral Hemorrhage: Where Are We Now? Current cardiology reports 2021; 23:162. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34599375>
5. Safouris A, Magoufis G, Tsivgoulis G. Emerging agents for the treatment and prevention of stroke: progress in clinical trials. Expert opinion on investigational drugs 2021; 30:1025-1035. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34555978>
6. Zhang X, Wang D, Tian Y *et al.* Risk Factors for Atorvastatin as a Monotherapy for Chronic Subdural Hematoma: A Retrospective Multifactor Analysis. Frontiers in aging neuroscience 2021; 13:726592. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34539386>
7. Bulwa ZB, Mendelson SJ, Brorson JR. Acute Secondary Prevention of Ischemic Stroke: Overlooked No Longer. Frontiers in neurology 2021; 12:701168. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34566845>
8. Li C, Ma M, Dong S *et al.* Statin Treatment in the Acute Phase and the Risk of Post-stroke Pneumonia: A Retrospective Cohort Study. Frontiers in neurology 2021; 12:635079. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34552547>
9. Lu G, Li Z. Statin Therapy on Cognitive Decline and Incident Dementia. J Am Coll Cardiol 2021; 78:e101. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34593131>
10. Zhou Z, Ryan J, Ernst ME *et al.* Reply: Statin Therapy on Cognitive Decline and Incident Dementia. J Am Coll Cardiol 2021; 78:e103. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34593132>
11. Collin BG, Raju D, Katsikas S. Statins, Enzyme CoQ(10) Supplement Use, and Cognitive Functioning. J Geriatr Psychiatry Neurol 2021:8919887211044747. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34493115>
12. Yang L, Li N, Yang L *et al.* Atorvastatin-Induced Absorption of Chronic Subdural Hematoma Is Partially Attributed to the Polarization of Macrophages. Journal of molecular neuroscience : MN 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34569007>

13. Liu CH, Lin YS, Sung PS *et al.* Colchicine Use and Risks of Stroke Recurrence in Acute Non-Cardiogenic Ischemic Stroke Patients: A Population-Based Cohort Study. Journal of personalized medicine 2021; 11.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34575712>
14. Sonaglioni A, Cara MD, Nicolosi GL *et al.* Rapid Risk Stratification of Acute Ischemic Stroke Patients in the Emergency Department: The Incremental Prognostic Role of Left Atrial Reservoir Strain. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2021; 30:106100. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34525440>
15. Yoon YH, Ahn JM, Kang DY *et al.* Association of Lipoprotein(a) With Recurrent Ischemic Events Following Percutaneous Coronary Intervention. JACC Cardiovasc Interv 2021; 14:2059-2068. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34556280>
16. Alikiaii B, Heidari Z, Bagherniya M *et al.* The Effect of Statins on C-Reactive Protein in Stroke Patients: A Systematic Review of Clinical Trials. Mediators Inflamm 2021; 2021:7104934. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34489618>
17. Liu W, Zhao XF, Liang YL *et al.* A retrospective study on the preventive effect of statin after carotid artery stenting. Medicine (Baltimore) 2021; 100:e26201.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34477113>

Triglycerides/HDL

1. Park MS, Youn JC, Kim EJ *et al.* Efficacy and Safety of Fenofibrate-Statin Combination Therapy in Patients With Inadequately Controlled Triglyceride Levels Despite Previous Statin Monotherapy: A Multicenter, Randomized, Double-blind, Phase IV Study. Clinical therapeutics 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34518033>
2. Shah T, McCarthy M, Nasir I *et al.* Design and rationale of the colchicine/statin for the prevention of COVID-19 complications (COLSTAT) trial. Contemporary clinical trials 2021:106547. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34461322>
3. Hernandez P, Passi N, Modarressi T *et al.* Clinical Management of Hypertriglyceridemia in the Prevention of Cardiovascular Disease and Pancreatitis. Curr Atheroscler Rep 2021; 23:72.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34515873>
4. Nusinovici S, Li H, Thakur S *et al.* High-Density Lipoprotein 3 Cholesterol and Primary Open-Angle Glaucoma: Metabolomics and Mendelian Randomization Analyses. Ophthalmology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34592243>

Trials

1. Venkataraman P, Huynh Q, Nicholls SJ *et al.* Impact of a coronary artery calcium-guided statin treatment protocol on cardiovascular risk at 12 months: Results from a pragmatic, randomised controlled trial. *Atherosclerosis* 2021; 334:57-65.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34482089>
2. Park MS, Youn JC, Kim EJ *et al.* Efficacy and Safety of Fenofibrate-Statin Combination Therapy in Patients With Inadequately Controlled Triglyceride Levels Despite Previous Statin Monotherapy: A Multicenter, Randomized, Double-blind, Phase IV Study. *Clinical therapeutics* 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34518033>
3. Oyama K, Giugliano RP, Tang M *et al.* Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial. *Eur Heart J* 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34537830>
4. Sardari S, Fallahi F, Emadi F *et al.* Daily Consumption of Caper Fruit Along With Atorvastatin Has Synergistic Effects in Hyperlipidemic Patients: Randomized Clinical Trial. *Galen Med J* 2019; 8:e1345.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34466497>
5. Shinohara K, Ikeda S, Enzan N *et al.* Efficacy of intensive lipid-lowering therapy with statins stratified by blood pressure levels in patients with type 2 diabetes mellitus and retinopathy: Insight from the EMPATHY study. *Hypertension research : official journal of the Japanese Society of Hypertension* 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34526672>
6. Davoodi L, Jafarpour H, Oladi Z *et al.* Atorvastatin therapy in COVID-19 adult inpatients: A double-blind, randomized controlled trial. *International journal of cardiology. Heart & vasculature* 2021; 36:100875.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34541293>
7. Verdickt S, Van der Schueren B, Vangoitsenhoven R *et al.* Belgian data of ODYSSEY APPRISE: stringent LDL-c targets are in reach when using all available tools. *Int J Clin Pract* 2021:e14916. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34551183>
8. Howard JP, Wood FA, Finegold JA *et al.* Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment. *J Am Coll Cardiol* 2021; 78:1210-1222.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34531021>
9. Toth PP. That Myalgia of Yours Is Not From Statin Intolerance. *J Am Coll Cardiol* 2021; 78:1223-1226. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34531022>
10. Asakura M, Hibi K, Shimizu W *et al.* Design and rationale of the EVOCATION trial: A prospective, randomized, exploratory study comparing the effect of evolocumab on coronary microvascular function after percutaneous coronary intervention in patients with stable coronary artery disease. *J Cardiol* 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34518072>

11. Delluc A, Ghanima W, Kovacs MJ *et al.* Statins for venous event reduction in patients with venous thromboembolism: A multicenter randomized controlled pilot trial assessing feasibility. Journal of thrombosis and haemostasis : JTH 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34564938>
12. Kramer JJ, Gu L, Moreira D *et al.* Statin Use and Lower Urinary Tract Symptoms Incidence and Progression in Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial. The Journal of urology 2021;101097ju0000000000002199. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34544265>
13. Lanzolla G, Sabini E, Leo M *et al.* Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial. The lancet. Diabetes & endocrinology 2021; 9:733-742. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34592164>
14. Pinto LCS, Mello APQ, Izar MCO *et al.* Main differences between two highly effective lipid-lowering therapies in subclasses of lipoproteins in patients with acute myocardial infarction. Lipids Health Dis 2021; 20:124. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34587943>
15. Trias F, Pintó X, Corbella E *et al.* Differences in the diabetogenic effect of statins in patients with prediabetes. The PRELIPID study. Med Clin (Barc) 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34517987>
16. Wang QN, Bao XY, Zou ZX *et al.* The role of atorvastatin in collateral circulation formation induced by encephaloduroarteriosynangiosis: a prospective trial. Neurosurg Focus 2021; 51:E9. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34469867>

Women and elderly

1. Abbasloo S, Aghaei Meybodi HR, Fahimfar N *et al.* The associations of statin intake and the trabecular bone score and bone mineral density status in elderly Iranian individuals: a cross-sectional analysis of the Bushehr Elderly Health (BEH) program. Arch Osteoporos 2021; 16:144. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34570258>
2. Klevmoen M, Bogsrud MP, Retterstøl K *et al.* Loss of statin treatment years during pregnancy and breastfeeding periods in women with familial hypercholesterolemia. Atherosclerosis 2021; 335:8-15. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34520888>
3. Vahedian-Azimi A, Bianconi V, Makvandi S *et al.* A systematic review and meta-analysis on the effects of statins on pregnancy outcomes. Atherosclerosis 2021; 336:1-11. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34601188>
4. Hsu J, Iversen T, Price M *et al.* Myocardial Infarction Care Among The Elderly: Declining Treatment With Increasing Age In Two Countries. Health Aff (Millwood) 2021; 40:1483-1490. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34495733>

5. Sarraju A, Spencer-Bonilla G, Chung S *et al.* Statin Use in Older Adults for Primary Cardiovascular Disease Prevention Across a Spectrum of Cardiovascular Risk. Journal of general internal medicine 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34505981>
6. Moon IT, Kang SH, Lee W *et al.* Impact of statin intensity on adverse cardiac and cerebrovascular events in older adult patients with myocardial infarction. Journal of geriatric cardiology : JGC 2021; 18:609-622.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34527027>
7. Fokina VM, Patrikeeva S, Wang XM *et al.* Role of Uptake Transporters OAT4, OATP2A1, and OATP1A2 in Human Placental Bio-disposition of Pravastatin. Journal of pharmaceutical sciences 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34597623>
8. Afrin S, El Sabeh M, Islam MS *et al.* Simvastatin modulates estrogen signaling in uterine leiomyoma via regulating receptor palmitoylation, trafficking and degradation. Pharmacol Res 2021; 172:105856.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34461224>